Review



human bladder carcinoma cell line j82  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC human bladder carcinoma cell line j82
    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and <t>J82</t> bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    Human Bladder Carcinoma Cell Line J82, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 798 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bladder carcinoma cell line j82/product/ATCC
    Average 96 stars, based on 798 article reviews
    human bladder carcinoma cell line j82 - by Bioz Stars, 2026-05
    96/100 stars

    Images

    1) Product Images from "Intravesical Delivery of P21 mRNA –Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer"

    Article Title: Intravesical Delivery of P21 mRNA –Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer

    Journal: The FASEB Journal

    doi: 10.1096/fj.202600049R

    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and J82 bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    Figure Legend Snippet: Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and J82 bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.

    Techniques Used: Biomarker Discovery, Expressing, Immunohistochemical staining, Staining, Microarray, Western Blot, Transfection, Control, Immunofluorescence



    Similar Products

    human bladder carcinoma cell line j82  (ATCC)
    96
    ATCC human bladder carcinoma cell line j82
    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and <t>J82</t> bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    Human Bladder Carcinoma Cell Line J82, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bladder carcinoma cell line j82/product/ATCC
    Average 96 stars, based on 1 article reviews
    human bladder carcinoma cell line j82 - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    t24 urinary bladder transitional carcinoma cells  (ATCC)
    98
    ATCC t24 urinary bladder transitional carcinoma cells
    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and <t>J82</t> bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    T24 Urinary Bladder Transitional Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/t24 urinary bladder transitional carcinoma cells/product/ATCC
    Average 98 stars, based on 1 article reviews
    t24 urinary bladder transitional carcinoma cells - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    human bladder transitional cell carcinoma t24 cells  (ATCC)
    98
    ATCC human bladder transitional cell carcinoma t24 cells
    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and <t>J82</t> bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    Human Bladder Transitional Cell Carcinoma T24 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bladder transitional cell carcinoma t24 cells/product/ATCC
    Average 98 stars, based on 1 article reviews
    human bladder transitional cell carcinoma t24 cells - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    t24 bladder transitional carcinoma cells  (ATCC)
    98
    ATCC t24 bladder transitional carcinoma cells
    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and <t>J82</t> bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    T24 Bladder Transitional Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/t24 bladder transitional carcinoma cells/product/ATCC
    Average 98 stars, based on 1 article reviews
    t24 bladder transitional carcinoma cells - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    mouse bladder carcinoma cell line mb49  (Procell Inc)
    86
    Procell Inc mouse bladder carcinoma cell line mb49
    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and <t>J82</t> bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    Mouse Bladder Carcinoma Cell Line Mb49, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse bladder carcinoma cell line mb49/product/Procell Inc
    Average 86 stars, based on 1 article reviews
    mouse bladder carcinoma cell line mb49 - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    human bladder carcinoma cell lines t24  (ATCC)
    98
    ATCC human bladder carcinoma cell lines t24
    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and <t>J82</t> bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    Human Bladder Carcinoma Cell Lines T24, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bladder carcinoma cell lines t24/product/ATCC
    Average 98 stars, based on 1 article reviews
    human bladder carcinoma cell lines t24 - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    human bladder epithelium carcinoma cells  (ATCC)
    97
    ATCC human bladder epithelium carcinoma cells
    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and <t>J82</t> bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    Human Bladder Epithelium Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bladder epithelium carcinoma cells/product/ATCC
    Average 97 stars, based on 1 article reviews
    human bladder epithelium carcinoma cells - by Bioz Stars, 2026-05
    97/100 stars
    		  Buy from Supplier
    urinary bladder transitional cell carcinoma cell lines t24  (ATCC)
    98
    ATCC urinary bladder transitional cell carcinoma cell lines t24
    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and <t>J82</t> bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    Urinary Bladder Transitional Cell Carcinoma Cell Lines T24, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/urinary bladder transitional cell carcinoma cell lines t24/product/ATCC
    Average 98 stars, based on 1 article reviews
    urinary bladder transitional cell carcinoma cell lines t24 - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    human bladder carcinoma cell line 5637  (Procell Inc)
    86
    Procell Inc human bladder carcinoma cell line 5637
    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and <t>J82</t> bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.
    Human Bladder Carcinoma Cell Line 5637, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bladder carcinoma cell line 5637/product/Procell Inc
    Average 86 stars, based on 1 article reviews
    human bladder carcinoma cell line 5637 - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and J82 bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.

    Journal: The FASEB Journal

    Article Title: Intravesical Delivery of P21 mRNA –Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer

    doi: 10.1096/fj.202600049R

    Figure Lengend Snippet: Rationale for selecting CDKN1A /p21 as a therapeutic target in bladder cancer and validation of p21 mRNA expression. (A) Pan‐cancer analysis of CDKN1A alteration frequencies based on TCGA datasets. The analysis was performed using the TIMER3 web server. (B) CDKN1A mRNA expression in bladder cancer and normal bladder tissues, shown as log2(TPM + 1), where TPM denotes transcripts per million. Data were analyzed using the TIMER3 web server. (C) Representative p21 immunohistochemical staining images from a bladder cancer tissue microarray stratified by pathological stage (Tis, T1, T2, T3, and T4). Scale bars, 200 μm. (D) Quantification of p21 H‐scores in Tis, T1, T2, T3, and T4 lesions. Compared with Tis lesions, T1, T2, T3, and T4 tumors showed significantly lower p21 H‐scores. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01 (one‐way ANOVA). (E) Western blot analysis of basal and p21 mRNA‐induced p21 protein expression in T24 and J82 bladder cancer cells. Basal p21 protein levels were very low in both cell lines, whereas transfection of p21 mRNA led to robust p21 expression. For p21 blots, both short‐exposure (se) and long‐exposure (le) images are shown. β‐Actin serves as a loading control. (F) Immunofluorescence analysis of EGFP‐HA and p21‐HA expression in T24 and J82 cells using an anti‐HA antibody. Nuclei were stained with DAPI. The p21‐HA signal was predominantly localized to the nucleus, whereas EGFP showed diffuse cytoplasmic distribution. Scale bars, 20 μm.

    Article Snippet: The human bladder carcinoma cell line J82 and the human embryonic kidney cell line HEK293T were purchased from the American Type Culture Collection (ATCC).

    Techniques: Biomarker Discovery, Expressing, Immunohistochemical staining, Staining, Microarray, Western Blot, Transfection, Control, Immunofluorescence